NCT06903416 Non-Invasive Neuromodulation for Upper Extremity Function in Spinal Cord Injury: A Crossover Trial
| NCT ID | NCT06903416 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | University of Alberta |
| Condition | Spinal Cord Injury Cervical |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-05-07 |
| Primary Completion | 2030-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 10 participants in total. It began in 2025-05-07 with a primary completion date of 2030-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study explores two promising therapies for restoring arm and hand function in people with chronic cervical spinal cord injury (SCI), a condition that affects independence and quality of life. It will compare transcutaneous spinal cord stimulation and paired corticospinal-motoneuronal stimulation, both combined with rehabilitation. Using a crossover design, participants will receive each therapy for two months, with a one-month washout period in between. Safety, effectiveness, and patient-reported outcomes like daily living ability and quality of life will be assessed, alongside changes in neural excitability. The results of this study may enable us to tailor treatments to individual needs, promoting personalized care and improved outcomes.
Eligibility Criteria
Inclusion Criteria: * Cervical (C2-C8) level SCI * \> 9 months post-injury * Traumatic SCI * AIS A-D * Stable dose of anti-spasmodics Exclusion Criteria: * individuals with injury to the nervous system other than to the spinal cord * pregnant
Contact & Investigator
Jessica M D'Amico, PhD
PRINCIPAL INVESTIGATOR
University of Alberta
Frequently Asked Questions
Who can join the NCT06903416 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Spinal Cord Injury Cervical. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06903416 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06903416 currently recruiting?
Yes, NCT06903416 is actively recruiting participants. Contact the research team at damico1@ualberta.ca for enrollment information.
Where is the NCT06903416 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT06903416 clinical trial?
NCT06903416 is sponsored by University of Alberta. The principal investigator is Jessica M D'Amico, PhD at University of Alberta. The trial plans to enroll 10 participants.